NOVO NORDISK (NVO) stocks fell more than 8% on Monday morning after the Danish Pharmaceutical Institute shared new data on the next-generation GLP-1 drug, Cagrisema.
The mixture of the company’s current blockbuster drugs ozempic and Wegovy, the core components of Cagrilintide and Semaglutide, is being tested for obesity and type 2 diabetes that can be injured for a week.
The results of the 3rd stage test show a weight loss of 15.7%, almost the same as the company’s current drug.
Close: March 10 4:02:20 EDT
Competing with ELI Lilly (Lly) Mounjaro and Zepbound, NOVO provided weight loss of more than 20% and gained the US market share last year.
In a note on the BMO analysis, “Semaglutide’s FDA shortages have been officially concluded, but the Zepbound script is maintained higher than Wegovy. We will watch this epidemiology closely to continue to evaluate NOVO’s opportunity to regain its market share in the US obesity market.”
In addition, producing CAGRIEMA is more difficult than the current weight loss drug, and analysts will not get significant benefits from NOVO.
LEERINK Partners Analyst David Risinger said on Monday, “Cagrisema is more difficult for manufacturing than Tirzepatide due to a dual chamber device.
NOVO is expected to be approved by the FDA in early 2026, and details of this year’s trial will be shared.
Anjalee Kachmli Yahoo Finance’s senior health journalists deal with everything that deals with pharmaceuticals, insurance, nursing services, digital health, PBM and health policy and politics. Of course, GLP-1 is included. Follow Anjalee in Social Media Platform X, LinkedIn and BlueSky. @anjkhem.
Click here for in -depth analysis of the latest health industry news and events affecting stock prices.
